Contrave Diet Pills

Contrave is a new diet pill being developed by Orexigen. The FDA is expected to rule on it in January, 2011.

Sunday, February 13, 2011

Orexigen Cutting Jobs to Conserve Cash

Orexigen(R) Cuts Jobs Due to FDA Response Letter

Orexigen(R) Therapeutics, Inc. staff will be reduced by about 40% to conserve cash after the Food and Drug Administration didn't approve Contrave requesting further studies on the long term effects of the drug on patients' cardiovascular systems. Mike Narachi, Orexigen's CEO, stated in a press release "We continue to believe in the potential of Contrave and look forward to discussions with the FDA. Unfortunately, given the near term uncertainty of Contrave approval, we felt it prudent to consolidate and focus our resources. We are deeply grateful for the dedication and tremendous effort provided by all of our colleagues who are impacted by this realignment."

As expected, Orexigen's (OREX) stock price took a hit after the FDA decision, dropping from the $8-9 range back to under $2.50 before coming back to Friday's close of $3.32.

Technorati Tags:

Labels: , , , , , , ,

0 Comments:

Post a Comment

<< Home